USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.
Visit United States Adopted Names FAQ to learn more.
Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].
In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following names for the drugs described are "under consideration" by the USAN Council:
December 2025
Aleniglipron: Treatment of type 2 diabetes mellitus (T2DM) and obesity
Aleniglipron l-arginine: Treatment of type 2 diabetes mellitus (T2DM) and obesity
Apazunersen: Treatment of Angelman Syndrome
Apazunersen sodium: Treatment of Angelman Syndrome
Birelentinib: Treatment of hematologic malignancies
Bleximenib: Treatment of leukemia
Bleximenib besylate: Treatment of leukemia
Efsudenermin alfa: Protein replacement for the missing EDA1 protein in patients with X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Elunetirom: Adjunctive treatment of Major Depressive Disorder Adjunctive treatment of Bipolar I or II Disorder
Nurandociguat: Treatment of patients with chronic kidney disease (CKD)
Nurandociguat hydrochloride: Treatment of patients with chronic kidney disease (CKD)
Plencifgene parvec: Treatment of Cystic Fibrosis lung disease (CF)
Polihexanide: Treatment of Acanthamoeba keratitis
Polihexanide hydrochloride: Treatment of Acanthamoeba keratitis
Rinatabart: Treatment of cancer
Rinatabart sesutecan: Treatment of cancer
Riztunitide: Treatment of neuroinflammation associated with amyotrophic lateral sclerosis (ALS)
Sesutecan: Treatment of cancer
Tenofovir alafenamide monofumarate: Prevention or treatment of HIV infection
Vidoflufolastat F 18: Radio diagnostic-agent
Vixticibart: Cardiovascular indications, treatment of heart failure and hypertension
November 2025
Asundexian: Thrombosis prevention
Balcinrenone: Treatment of heart failure
Bemarituzumab: Antineoplastic, treatment of FGFR2b-overexpressing solid tumors (e.g., gastric cancer)
Casdatifan: Antineoplastic
Dibotatug: Antineoplastic
Emodepside: Treatment of gastrointestinal infections caused by whipworm (Trichuris trichiura), hookworm (Necator americanus or Ancylostoma duodenale), and roundworm (Ascaris lumbricoides)
Glovadalen: Treatment of Parkinson's disease
Laroprovstat: Treatment of dyslipidemia
Lotivibart: Treatment of HIV infection
Luvomeran: Treatment of lung disease
Monalizumab: Antineoplastic
Narmafotinib: Treatment of cancer and fibrotic conditions
Narmafotinib tartrate: Treatment of cancer and fibrotic conditions
Pevifoscorvir sodium: Treatment of Chronic Hepatitis B Virus Infection and Hepatitis D Virus Infection
Sonruvetcel: Cellular therapy intended for the management of refractory feline chronic gingivostomatitis (FCG)
Ulacamten: Treatment of heart failure with preserved ejection fraction
Vispacabtagene regedleucel: Treatment of patients with relapsed/refractory B cell non-Hodgkin lymphomas (r/r B-NHL)
Xelafaslatide: Treatment for macula-off rhegmatogenous retinal detachment (RRD), geographic atrophy (GA) associated with age-related macular degeneration (AMD) and open-angle glaucoma (OAG)
Zamubafusp alfa: Treatment of amyloidosis
October 2025
Aletekitug: Treatment of atopic dermatitis
Amsulostat: Treatment of myelofibrosis
Amsulostat hydrochloride: Treatment of myelofibrosis
Delpacibart: Treatment of muscular dystrophy diseases
Delpacibart zotadirsen: Treatment of muscular dystrophy diseases
Direclidine: Treatment of schizophrenia
Direclidine citrate: Treatment of schizophrenia
Lanerkitug: Antineoplastic
Linaprazan glurate: Treatment of gastroesophageal reflux disease
Linaprazan glurate hydrochloride: Treatment of gastroesophageal reflux disease
Linoserpaturev: Treatment of residual or recurrent high grade or malignant gliomas
Oveporexton: Treatment of narcolepsy
Nivisnebart: Treatment of Alzheimer’s disease (AD) and Parkinson’s disease (PD)
Orevandrodeg: Treatment of prostate cancer
Persicabtagene lemgedleucel: Treatment of B-cell malignancies and Autoimmune Diseases
Sonelokimab: Treatment of inflammatory diseases
Sonruvetcel: Cellular therapy intended for the management of refractory feline chronic gingivostomatitis (FCG)
Tambiciclib: Treatment of relapsed/refractory hematologic malignancies
Turigrobart: Treatment of chronic pain
Usnoflast: Treatment of Amyotrophic lateral sclerosis (ALS), Parkinson's Disease (PD) and other Inflammatory conditions
Zabilugene almadenorepvec: Antineoplastic
